What is the enterprise number of THEODORUS IV?

The enterprise number of THEODORUS IV is BE0707902931.

What is the address of THEODORUS IV?

The registered office of THEODORUS IV is located at Researchdreef 12, 1070 Anderlecht.

When was THEODORUS IV founded?

THEODORUS IV was founded on 8 October 2018.

Does THEODORUS IV have a website?

No website is currently known for THEODORUS IV.

How much profit did THEODORUS IV make in 2024?

THEODORUS IV recorded a loss after taxes of € 2,408,224 in financial year 2024.

What is the revenue of THEODORUS IV?

As a small company, THEODORUS IV is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € -717,536.

Where can I find the annual accounts of THEODORUS IV?

THEODORUS IV files its annual accounts with the Central Balance Sheet Office of the National Bank of Belgium. The key figures for recent financial years are available for free on this page.

Who are the directors of THEODORUS IV?

According to the 2024 annual accounts, the directors of THEODORUS IV are: Finadvize SRL, Finance & Invest.brussels, Université Livre de Bruxelles, Square L SA, 50° North Ventures Sa, Société Fédérale de Participations et d'Investissement SA, BNP Paribas Fortis Private Equity Management SA, Alexandre Franco.

Who are the shareholders of THEODORUS IV?

According to the 2024 annual accounts, the shareholders of THEODORUS IV are: Société Fédérale de Participations et d'Investissements (30.4%), Sambrinvest Spin-Off/Spin-Out SA (15.2%).

THEODORUS IV (Public Limited) - Anderlecht (1070) - BE0707902931

Financials

Financial year 2024

Worth noting

A loss two years in a row.

Gross margin

€ -717,536

▲ 24% vs 2023

Profit

Caution

€ -2.4 million

▼ 6% vs 2023

Debts

Low

€ 61,539

▼ 72% vs 2023

THEODORUS IV from Anderlecht, company number BE0707902931, closed financial year 2024 with a result of € -2.4 million after tax. For that financial year THEODORUS IV recorded a gross margin of € -717,536 and equity of € 12 million. Compared with financial year 2023, the result moved from € -2.3 million to € -2.4 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 14, 2025.

What happened at THEODORUS IV?

What happened at THEODORUS IV in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2030 Finadvize SRL stepped down as director. NBB
2030 Finance & Invest.brussels stepped down as director. NBB
2030 Université Livre de Bruxelles stepped down as director. NBB
2030 Square L SA stepped down as director. NBB
2030 50° North Ventures Sa stepped down as director. NBB
2030 Société Fédérale de Participations et d'Investissement SA stepped down as director. NBB
2030 BNP Paribas Fortis Private Equity Management SA stepped down as director. NBB
2030 Alexandre Franco stepped down as director. NBB

In short

From € 872,230 loss in 2021 to € 2.4 million loss in 2024.

Original PDFs at the National Bank ↗

A new publication or filing at THEODORUS IV? We notify you, reason included.

Follow THEODORUS IV

Need more data?

History

Every financial year, as far back as the National Bank goes.

Buffer

How long does the company survive without income?

Credit limit

Indicative credit limit, computed from the real figures.

Alerts

New annual account: profit halved. New

Gazette: capital increase of 250k. New

News about who you follow, reason included.

Databakkes Pro · first month free

Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.

Management

Société Fédérale de Participations et d'Investissements 30.4%

Sambrinvest Spin-Off/Spin-Out SA 15.2%

THEODORUS IV

GEPECERON (ouverture faillite) 60%

INHATARGET THERAPEUTICS 31.6%

KAPCARE 29.7%

NEUVASQ BIOTECHNOLOGIES 19.7%

The shares are held by Société Fédérale de Participations et d'Investissements (30.4%) and Sambrinvest Spin-Off/Spin-Out SA (15.2%). It owns 60% of GEPECERON (ouverture faillite), 31.6% of INHATARGET THERAPEUTICS, 29.7% of KAPCARE, 19.7% of NEUVASQ BIOTECHNOLOGIES and 18.9% of NEOMABS BIOTECHNOLOGIES INC itself.

See the full network in the app